Takeda to invest ¥100 B in new facility for plasma-derived therapies in Japan
Takeda Pharmaceutical will invest approximately 100 billion yen (¥) to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. The new state-of-the-art facility will be the largest of its kind in the country and is expected to be operational by around 2030. The new site increases the c…
